NASDAQ: ADVMAdverum Biotechnologies Inc Stock
$10.19-0.81 (-7.36%)
Updated Apr 24, 2024
ADVM Price
$10.19
Fair Value Price
-$0.31
Market Cap
$211.49M
52 Week Low
$7.10
52 Week High
$29.70
P/E
-0.88x
P/B
2.53x
P/S
21.08x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.60M
Earnings
-$117.17M
Gross Margin
100%
Operating Margin
-3,284.53%
Profit Margin
-3,254.6%
Debt to Equity
1.07
Operating Cash Flow
-$91M
Beta
1.12
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ADVM Overview
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ADVM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ADVM ($10.19) is overvalued by 3,382.52% relative to our estimate of its Fair Value price of -$0.31 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ADVM ($10.19) is not significantly undervalued (3,382.52%) relative to our estimate of its Fair Value price of -$0.31 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ADVM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ADVM due diligence checks available for Premium users.
Be the first to know about important ADVM news, forecast changes, insider trades & much more!
ADVM News
Valuation
ADVM fair value
Fair Value of ADVM stock based on Discounted Cash Flow (DCF)
Price
$10.19
Fair Value
-$0.31
Undervalued by
3,382.52%
ADVM ($10.19) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ADVM ($10.19) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ADVM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ADVM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.88x
Industry
15.69x
Market
41.27x
ADVM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.53x
Industry
5.86x
ADVM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ADVM's financial health
Profit margin
Revenue
$0.0
Net Income
-$23.7M
Profit Margin
0%
ADVM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ADVM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$173.0M
Liabilities
$89.5M
Debt to equity
1.07
ADVM's short-term assets ($102.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ADVM's short-term assets ($102.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ADVM's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ADVM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$21.3M
Investing
-$9.9M
Financing
$166.0k
ADVM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ADVM vs Biotech Stocks
Adverum Biotechnologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.